ECSP21087921A - Materiales y métodos para modular la inmunidad mediada por células t - Google Patents

Materiales y métodos para modular la inmunidad mediada por células t

Info

Publication number
ECSP21087921A
ECSP21087921A ECSENADI202187921A ECDI202187921A ECSP21087921A EC SP21087921 A ECSP21087921 A EC SP21087921A EC SENADI202187921 A ECSENADI202187921 A EC SENADI202187921A EC DI202187921 A ECDI202187921 A EC DI202187921A EC SP21087921 A ECSP21087921 A EC SP21087921A
Authority
EC
Ecuador
Prior art keywords
methods
antibodies
modulating
cell
materials
Prior art date
Application number
ECSENADI202187921A
Other languages
English (en)
Inventor
Sanjaya Singh
Iqbal Grewal
Rajkumar Ganesan
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of ECSP21087921A publication Critical patent/ECSP21087921A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen anticuerpos anti-TRGV9 o fragmentos de unión al antígeno de estos. También se describen ácidos nucleicos que codifican los anticuerpos, composiciones que comprenden los anticuerpos, métodos para producir los anticuerpos y métodos para usar los anticuerpos para tratar o prevenir enfermedades, tales como el cáncer.
ECSENADI202187921A 2019-05-08 2021-12-03 Materiales y métodos para modular la inmunidad mediada por células t ECSP21087921A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962844966P 2019-05-08 2019-05-08
US201962844976P 2019-05-08 2019-05-08
US201962844959P 2019-05-08 2019-05-08
US201962844995P 2019-05-08 2019-05-08
US201962844970P 2019-05-08 2019-05-08

Publications (1)

Publication Number Publication Date
ECSP21087921A true ECSP21087921A (es) 2022-01-31

Family

ID=73051172

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202187921A ECSP21087921A (es) 2019-05-08 2021-12-03 Materiales y métodos para modular la inmunidad mediada por células t

Country Status (21)

Country Link
US (2) US11667712B2 (es)
EP (1) EP3965818A4 (es)
JP (1) JP2022533538A (es)
KR (1) KR20220017892A (es)
CN (1) CN113966231A (es)
AU (1) AU2020267504A1 (es)
BR (1) BR112021022089A2 (es)
CA (1) CA3139508A1 (es)
CL (1) CL2021002905A1 (es)
CO (1) CO2021015998A2 (es)
CR (1) CR20210548A (es)
DO (1) DOP2021000229A (es)
EC (1) ECSP21087921A (es)
IL (1) IL287817A (es)
JO (1) JOP20210297A1 (es)
MA (1) MA55903A (es)
MX (1) MX2021013532A (es)
PE (1) PE20220763A1 (es)
SG (1) SG11202112021QA (es)
TW (1) TW202108618A (es)
WO (1) WO2020227457A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201706128PA (en) 2015-01-27 2017-08-30 Lava Therapeutics B V Single domain antibodies targeting cd1d
EA202190773A1 (ru) 2018-09-19 2021-06-21 Лава Терапьютикс Б.В. CD1d ИММУНОГЛОБУЛИН ДВОЙНОГО ДЕЙСТВИЯ
EP4110390A1 (en) * 2020-02-27 2023-01-04 Janssen Biotech, Inc. Materials and methods for modulating an immune response
US20210284731A1 (en) * 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
UY39488A (es) 2020-10-28 2022-04-29 Janssen Biotech Inc Composiciones y métodos para modular la inmunidad mediada por la cadena delta gamma
JP2024507937A (ja) 2021-02-26 2024-02-21 ラヴァ・セラピューティクス・エヌ・ヴイ Cd123及びガンマデルタt細胞受容体に結合する抗体

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2005538682A (ja) 2001-12-03 2005-12-22 アブジェニックス・インコーポレーテッド カルボキシックアンヒドラーゼix(caix)腫瘍抗原に対する抗体
MX2007002856A (es) 2004-09-02 2007-09-25 Genentech Inc Metodos para el uso de ligandos receptores de muerte y anticuerpos c20.
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
JP5474531B2 (ja) 2006-03-24 2014-04-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 操作されたヘテロ二量体タンパク質ドメイン
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
WO2009018386A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク,インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
BR112012004777A2 (pt) 2009-09-03 2019-09-24 Genentech Inc métodos para tratar diagnósticar e monitorar artrite reumatoide
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
AU2011285922B2 (en) 2010-08-05 2016-06-16 Anaptysbio, Inc. Antibodies directed against IL-17
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
PE20141521A1 (es) 2011-08-23 2014-10-25 Roche Glycart Ag Moleculas biespecificas de union a antigeno activadoras de celulas t
JP6326371B2 (ja) 2011-11-04 2018-05-16 ザイムワークス,インコーポレイテッド Fcドメインにおける変異を有する安定なヘテロ二量体抗体デザイン
HUE033245T2 (hu) * 2011-12-19 2017-11-28 Synimmune Gmbh Bispecifikus ellenanyag molekula
EP3060059A4 (en) * 2013-10-25 2017-11-01 Board of Regents, The University of Texas System Polyclonal gamma delta t cells for immunotherapy
MX2016013332A (es) * 2014-04-10 2017-05-01 Stichting Vumc Receptores de células t vy9vd2 humanas que se unen a inmunoglobulinas.
MA53355A (fr) 2015-05-29 2022-03-16 Agenus Inc Anticorps anti-ctla-4 et leurs procédés d'utilisation
JP7291339B2 (ja) 2016-12-26 2023-06-15 協和キリン株式会社 ミエリンオリゴデンドロサイト糖タンパク質に結合する抗体
US11236145B2 (en) * 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
WO2019147735A1 (en) 2018-01-23 2019-08-01 New York University Antibodies specific to delta 1 chain of t cell receptor
EP4110390A1 (en) 2020-02-27 2023-01-04 Janssen Biotech, Inc. Materials and methods for modulating an immune response
US20210284731A1 (en) 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
UY39488A (es) 2020-10-28 2022-04-29 Janssen Biotech Inc Composiciones y métodos para modular la inmunidad mediada por la cadena delta gamma

Also Published As

Publication number Publication date
PE20220763A1 (es) 2022-05-16
AU2020267504A1 (en) 2021-12-02
CL2021002905A1 (es) 2022-06-17
CA3139508A1 (en) 2020-11-12
EP3965818A4 (en) 2023-05-31
US20240150464A1 (en) 2024-05-09
CR20210548A (es) 2022-02-11
IL287817A (en) 2022-01-01
TW202108618A (zh) 2021-03-01
CN113966231A (zh) 2022-01-21
MX2021013532A (es) 2022-02-11
CO2021015998A2 (es) 2021-12-10
SG11202112021QA (en) 2021-11-29
US11667712B2 (en) 2023-06-06
KR20220017892A (ko) 2022-02-14
US20210032338A1 (en) 2021-02-04
WO2020227457A1 (en) 2020-11-12
JP2022533538A (ja) 2022-07-25
BR112021022089A2 (pt) 2022-02-08
DOP2021000229A (es) 2022-07-31
JOP20210297A1 (ar) 2023-01-30
MA55903A (fr) 2022-03-16
EP3965818A1 (en) 2022-03-16

Similar Documents

Publication Publication Date Title
CL2020003028A1 (es) Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos.
ECSP21087921A (es) Materiales y métodos para modular la inmunidad mediada por células t
AR111288A1 (es) Anticuerpos anti-phf-tau y sus usos
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
BR112021020629A2 (pt) Compostos bicíclicos
CO2018012374A2 (es) Moléculas de anticuerpo para el tratamiento del cáncer
AR115389A1 (es) Anticuerpo antagonista de cd73
CO2019012329A2 (es) Polipéptidos que antagonizan la señalización wnt en células tumorales
BR112019004711A2 (pt) receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
UY39416A (es) Moléculas de direccionamiento inmunes multiespecíficas y usos de estas
CO2018010827A2 (es) Anticuerpos anti-factor bb del complemento y usos de estos
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
CO2022001977A2 (es) Anticuerpos anti-cd96 y sus métodos de uso
CL2022002766A1 (es) Anticuerpos anti-phf-pau y sus usos.
EA202190807A1 (ru) Антитела к синуклеину
UY39127A (es) Materiales y métodos para modular la inmunidad mediada por cadena delta
CO2019009815A2 (es) Combinaciones farmacéuticas
CL2021001615A1 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
UY39699A (es) Anticuerpos anti-tau y usos de estos
UY39415A (es) Métodos y composiciones para modular la inmunidad mediada por cadenas beta
EA202092122A1 (ru) Антитела против tip-1 и их применения
EA202193035A1 (ru) Материалы и способы для модуляции иммунитета, опосредованного т-клетками
AR115424A1 (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33 / anti-cd3 y usos de estos
CO2022003324A2 (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares